Abstract
Objective
Study design
Results
Conclusion
Key words
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyArticle info
Publication history
Publication stage
In Press Journal Pre-ProofFootnotes
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Declaration of Competing Interest
The authors have no relevant financial or non-financial interests to disclose.
Submission declaration
The content of this study was partially presented previously at MASCC/ISOO 2022 Annual meeting. Additionally, a previous version of this study is also available as a preprint on Research Square platform - DOI: 10.21203/rs.3.rs-1661856/v1.
Statement of Clinical Relevance
EGFR inhibitors such as panitumumab have been associated with changes in oral mucosa. Although panitumumab-containing regimes seem generally well accepted, oral lesions among other adverse events associated with this targeted agent may affect the tolerability of patients undergoing cancer treatment.
Acknowledgements
The authors would like to thank Dr. Jorge Sabbaga, head of gastrointestinal clinical oncology department of Instituto do Câncer do Estado de São Paulo to the research support.
